2018 - Ensure Secure, Efficient Real World Evidence Development With a Data-Centric Approach

HEOR, Market Access, IT, and Clinical innovators throughout the healthcare ecosystem are turning to real world evidence (RWE) to develop greater insight into the value of drugs, translational medicine and patient outcomes.
With FDA’s Janet Woodcock making a statement that the “the clinical trials system is broken,” coupled with a rise in RWE initiatives by regulatory agencies – including the 21st Century Cures Act and the IMI GetReal project – the need to leverage RWE to establish the value and validity of drugs has taken on greater urgency for organizations across the ecosystem.